Aytu Biopharma
Aytu Biopharma is a specialty pharmaceutical company focused on developing and commercializing products for various healthcare conditions. The company primarily targets urological indications, with an emphasis on male sexual dysfunction and male infertility, while exploring opportunities in other related areas. In addition to its urological focus, Aytu Biopharma offers prescription therapeutics for attention deficit hyperactivity disorder and other common pediatric conditions. The company is also advancing a therapeutic pipeline that includes AR101/enzastaurin, a prospective treatment for vascular Ehlers-Danlos Syndrome, a rare genetic disorder characterized by serious health complications. This treatment has received Orphan Drug designation from the FDA, highlighting its potential importance in addressing unmet medical needs. Aytu Biopharma’s diverse portfolio reflects its commitment to improving patient outcomes across various therapeutic areas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.